

2024 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium September 21-24, 2024

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Andreas L. Birkenfeld, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Petter Björnstad, MD	Consultant for AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Meyer Squibb, Eli Lilly, Horizon Therapeutics/Amgen, LG Chem, Novo Nordisk, Sanofi, and XORTX Scientific; and Grant/Research Support from AstraZeneca, Eli Lilly, Horizon Therapeutics/Amgen, Merck, and Novo Nordisk.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Charles Brenner, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4 Planner Moderator
Rotonya M. Carr, MD	Consultant for Intercept, and Novo Nordisk; and Grant/Research Support from Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Lisa Chow, MD, MS	Grant/Research Support from Dexcom.	None	2 & 4
David D’Alessio, MD	Consultant for Altimmune, Arrowhead Pharmaceuticals, Eli Lilly and Company, MBX Biosciences, Structure Therapeutics, and Sun Pharma; and Grant/Research Support from Astellas, BMS, Eli Lilly, and Nimbus Therapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Carmella Evans-Molina, MD, PhD	Consultant for Avotres, DiogenyX, INNODIA, Isla Technologies, and Neurodon; and Grant/Research Support from Astellas, BMS, Eli Lilly, and Nimbus Therapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of:</i> <i>Baracitinib and Verapamil</i>	2, 3, 4 & 6 Planner Moderator
Paul W. Franks, PhD	Consultant for Novo Nordisk A/S, and Zoe Global Ltd.; and Grant/Research Support from Innovative Medicines Initiative.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of:</i> <i>Metformin, Sulfonylureas, and Incretin pathway drugs</i>	3, 4 & 6
Jose M. Garcia, MD, PhD	Grant/Research Support from Pfizer and Novo Nordisk.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4 & 6
Adolfo Garcia-Ocaña, PhD	Consultant for Sun Pharmaceutical Industries; and Other Financial Relationship – (Patent)	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Robert E. Gerszten, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Maria B. Grant, MD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Tamara S. Hannon, MD, MS	Consultant for Eli Lilly, Inc. Grant/Research Support from Eli Lilly, Inc., and Novo Nordisk.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
David M. Harlan, MD	Consultant for Diabeloop, Novartis, and Vertex Pharmaceuticals.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 4 & 6 Planner Moderator
Richard Holbrook	I do not have any relevant financial relationships with any ineligible companies.	None	N/A
Emina Huang, MD, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	4
Barbara B. Kahn, MD	Consultant for Arrowhead Pharmaceuticals, Janssen Research & Development/Johnson & Johnson, and Vida Ventures Advisors, LLC.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Steven E. Kahn, MB, ChB	Consultant for Abarceo Pharma, AltPep, Amgen, Anji Pharmaceuticals, Biomea Fusion, Boehringer Ingelheim, Eli Lilly, Merck, Neurimmune, Novo Nordisk, and Oramed Pharmaceuticals; and Grant/Research Support from Corcept Therapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4 Planner Moderator
Fouad Kandeel, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4 Planner Moderator
Megan Moriarty Kelsey, MD, MS	Grant/Research Support from Rhythm Pharmaceuticals.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of:</i> <i>Pioglitazone, Semaglutide, Tirzepatide, and Canagliflozin</i>	1, 2, 4 & 6

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Hirotake Komatsu, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Rama Natarajan, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4 Planner Moderator
David M. Nathan, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4
Alessandro Parente, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Rachel Perry, PhD	I do not have any relevant financial relationships with any ineligible companies.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Dichloroacetate</i>	4
Kelly Person, CPA, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	N/A
Anne Peters, MD	Consultant for Abbott Diabetes Care, and Vertex Pharmaceuticals; and Grant/Research Support from Abbott Diabetes Care, Dexcom, and Insulet.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 5 & 6
Jane EB Reusch, MD	Consultant for Medtronic.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6 Planner Moderator
Michael R. Rickels, MD, MS	Consultant for Sernova Corp., and Vertex Pharmaceuticals; and Grant/Research Support from Dompé farmaceutici SpA.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Stem Cell-Derived Islets</i>	1, 2, 3, 4, 5 & 6
Michael Roden, MD	Consultant for Echosens, Madrigal Pharmaceuticals, MSD Sharp & Dohme GmbH/Merck, and Target RWE; Grant/Research Support from Boehringer Ingelheim, and Novo Nordisk; and on the Speakers Bureau for AstraZeneca, Boehringer Ingelheim, Madrigal Pharmaceuticals, and Novo Nordisk.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Justin Ryder, PhD	Consultant for Calorify; and Grant/Research Support from Boehringer Ingelheim.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
Ann Marie Schmidt, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1
Sarah Shuck, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Andrew F. Stewart, MD	I do not have any relevant financial relationships with any ineligible companies.	None	4 & 6 Planner Moderator
Debbie C. Thurmond, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	5 & 6 Moderator

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Jay Tinklepaugh, PhD	Grant/Research Support from Boehringer Ingelheim, InSphero, and Neurodon LLC.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	N/A Moderator
Alice A. Tomei, PhD	Consultant for ISLA Pharmaceuticals; and Royalties from Sernova Corp.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4, 5 & 6
Miriam S. Udler, MD, PhD	Grant/Research Support from Novo Nordisk.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Rupangi Vasavada, PhD	Other Financial Relationship – (Patent)	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Christina Vidal, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Susan Weinberg, MA	I do not have any relevant financial relationships with any ineligible companies.	None	N/A
Angela Williams	I do not have any relevant financial relationships with any ineligible companies.	None	N/A

1. The ACCME defines “relevant” financial relationships” as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an “ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

CORE COMPETENCIES INFORMATION SHEET

PRACTICE-BASED LEARNING AND IMPROVEMENT

Physicians must be able to investigate and evaluate their patient care practices, appraise and assimilate scientific evidence, and improve their patient care practices. **CME programs address these issues if the topics relate to:**

- analyzing practice experience and performing practice-based improvement activities using a systematic methodology
- locating, appraising, and assimilating evidence from scientific studies related to their patients' health problems
- obtaining and using information about their own population of patients and the larger population from which their patients are drawn
- applying knowledge of study designs and statistical methods to the appraisal of clinical studies and other information on diagnostic and therapeutic effectiveness
- using information technology to manage information, access on-line medical information; and support their own education
- facilitating the learning of students and other health care professionals

PATIENT CARE

Physicians must be able to provide patient care that is compassionate, appropriate, and effective for the treatment of health problems and the promotion of health. **CME programs address these issues if they address topics related to:**

- The ability to communicate effectively and demonstrate caring and respectful behaviors when interacting with patients and their families;
- gathering essential and accurate information about their patients
- making informed decisions about diagnostic and therapeutic interventions based on patient information and preferences, up-to-date scientific evidence, and clinical judgment
- developing and carrying out patient management plans
- counseling and educating patients and their families
- using information technology to support patient care decisions and patient education
- performing competently all medical and invasive procedures considered essential for the area of practice
- providing health care services aimed at preventing health problems or maintaining health
- working with health care professionals, including those from other disciplines, to provide patient-focused care

SYSTEMS-BASED PRACTICE

Physicians must demonstrate an awareness of and responsiveness to the larger context and system of health care and the ability to effectively call on system resources to provide care that is of optimal value. **CME programs address these issues if the topics relate to:**

- understanding how their patient care and other professional practices affect other health care professionals, the health care organization, and the larger society and how these elements of the system affect their own practice
- knowing how types of medical practice and delivery systems differ from one another, including methods of controlling health care costs and allocating resources
- practicing cost-effective health care and resource allocation that does not compromise quality of care
- advocating for quality patient care and assisting patients in dealing with system complexities
- knowing how to partner with health care managers and health care providers to assess, coordinate, and improve health care and knowing how these activities can affect system performance

MEDICAL KNOWLEDGE

Physicians must demonstrate knowledge about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care. **CME programs address these issues if the topics relate to:**

- demonstration of an investigatory and analytic thinking approach to clinical situations
- knowledge and application of the basic and clinically supportive sciences which are appropriate to their discipline

INTERPERSONAL AND COMMUNICATION SKILLS

Physicians must be able to demonstrate interpersonal and communication skills that result in effective information exchange and teaming with patients, their patients families, and professional associates. **CME programs address these issues if the topics relate to:**

- creating and sustaining a therapeutic and ethically sound relationship with patients
- using effective listening skills and eliciting and providing information using effective nonverbal, explanatory, questioning, and writing skills
- working effectively with others as a member or leader of a health care team or other professional group

PROFESSIONALISM

Physicians must demonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to a diverse patient population. **CME programs address these issues if the topics relate to:**

- demonstrating respect, compassion, and integrity; responsiveness to the needs of patients and society that supersedes self-interest; accountability to patients, society, and the profession; and a commitment to excellence and on-going professional development
- demonstrating a commitment to ethical principles pertaining to provision or withholding of clinical care, confidentiality of patient information, informed consent, and business practices
- demonstrating sensitivity and responsiveness to patients' culture, age, gender, and disabilities